At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 94 enrolled
Drug / intervention
UISH001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel, Placebo-controlled Study for the Assessment of the Safety and Efficacy of UISH001 for the Symptomatic Improvement of Urinary Incontinence
In Brief
A Phase 2 clinical trial evaluating UISH001 and matching placebo for Urinary Incontinence. Completed, enrolled 94 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Incontinence
CountriesUnited States
CollaboratorsNorwich Clinical Research Associates Ltd.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedApr 2011
Primary CompletionMay 2012
TodayJul 2026
First PostedApr 22, 2011
Enrollment StartApr 1, 2011
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.2 years ago
Interventions
UISH001drug
sublingual dosing, 1 drop 3 times a day
matching placebodrug
sublingual dosing,1 drop 3 times a day